Анастрозол

Quick links

Choose a section

Quick links to important sections

Advertisements

Анастрозол

Advertisements
Advertisements

Treatment option: Cancer, Breast Cancer

Advertisements

Overview of Анастрозол

Property Description
Active ingredient Anastrozole (INN)
Form Oral tablet (Film-coated)
Pharmacological class Non-steroidal Aromatase Inhibitor (AI)
General purpose Endocrine therapy / Estrogen suppression
Origin Synthetic organic compound
Rx Status Prescription-only

What Type of Medicine is Анастрозол?

Анастрозол is a synthetic, prescription-only medication widely recognized as a non-steroidal Aromatase Inhibitor (AI), placing it within the therapeutic group of Antineoplastic agents. The medication's active ingredient is Anastrozole, delivered as a standardized film-coated tablet for oral dosage. Its classification as non-steroidal distinguishes it from older hormonal agents with steroidal structures. This specific designation means the drug is utilized for its targeted effect on endocrine function.

How Does Анастрозол Work at a General Level?

The core mechanism involves achieving effective estrogen biosynthesis suppression throughout the body, a process that is clinically recognized as essential for managing certain hormone-driven conditions. This is accomplished by the drug's high selectivity in blocking the aromatase enzyme (CYP19A1), which is the enzyme responsible for converting androgens into estrogens in peripheral tissues. Pharmacological studies confirm that this mechanism leads to a significant reduction in circulating estrogen levels, which is the foundational goal of this endocrine therapy approach.

Composition and Chemical Origin

The medication is a single-ingredient formulation based on the synthetic organic compound, Anastrozole. This active substance belongs to the 1,2,4-triazole derivative class, a chemical structure engineered to ensure highly specific binding to the target enzyme. The development of this third-generation compound is considered an advance in therapeutics, offering advantages over earlier treatments, particularly in postmenopausal patients.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with Анастрозол?

Possible Side Effects and Safety Information

The safety profile of Anastrozole is officially documented in regulatory sources and primarily reflects the consequences of its intended oestrogen-suppressing action. Side effects are classified by their frequency and the system or organ class affected.


Frequency-Categorized Adverse Reactions

The most frequently reported adverse reactions, classified as Very Common (occurring in 1 in 10 patients or more), include hot flushes, arthralgia (joint pain), joint stiffness, headache, and asthenia (weakness/fatigue). Reactions listed as Common (up to 1 in 10 patients) often involve the musculoskeletal and nervous systems, such as osteoporosis, bone pain, myalgia (muscle pain), vomiting, diarrhoea, hair thinning (alopecia), peripheral oedema, and hypertension.

Rarely documented reactions include severe conditions like Stevens-Johnson Syndrome and Angioedema, which are classified as Very Rare, and Hepatitis, which is classified as Uncommon.


Serious Safety Considerations and Constraints

The long-term effect of oestrogen suppression is associated with a risk of decreased bone mineral density, increasing the incidence of fractures over time. Official labeling notes an increased incidence of ischemic cardiovascular events in patients with pre-existing heart disease. The medicine is contraindicated for use in premenopausal women and during pregnancy or lactation. Caution is also specified for use in patients with severe hepatic impairment or severe renal impairment. Co-administration with tamoxifen or oestrogen-containing therapies should be avoided as this may diminish Anastrozole's pharmacological action.

Advertisements

Overdose and Emergency Response

Overdose Scope: Official Regulatory Information

The official profile for Anastrozole overdose is defined by limited clinical experience of accidental overdosage. High single doses tested in studies were reported as well tolerated, and the dose resulting in life-threatening symptoms has not been established.

Entity Official Regulatory Statement
Documented Overdose Presentations Gastrointestinal symptoms are listed, specifically feeling sick (nausea), vomiting, and diarrhoea.
Dose-related or Exposure-related Factors In management, consideration must be given to the possibility that multiple agents may have been taken.
Emergency-Response Statements Contact your regional poison control centre for management of a suspected drug overdose.
When immediate medical help is required Seek immediate medical attention or call emergency services (e.g., 911) if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Management and Classification

  • No specific antidote is known or exists for overdosage; treatment is required to be symptomatic and supportive.
  • General supportive care is indicated, which includes frequent monitoring of vital signs and close observation of the patient.
  • The use of dialysis may be helpful due to the low protein binding of Anastrozole.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by the absence of a specific antidote and the need for symptomatic and supportive care. This structure necessitates immediate emergency medical consultation upon the manifestation of severe, systemic symptoms such as loss of consciousness or difficulty breathing, exactly as described in government guidelines.

Advertisements

Therapeutic Uses of Анастрозол

What Anastrozole Treats: Main Uses and Benefits

The primary therapeutic use of Anastrozole is focused on conditions where disease activity is linked to the presence of the hormone estrogen, primarily in postmenopausal women. The medication is commonly used across conditions presenting with acute episodes, relevant in situations involving hormone-driven disease, such as estrogen receptor-positive (ER+) breast cancer. The overall benefit is that it helps address symptom clusters that may become intense or disruptive.

Anastrozole is relevant across domains where additional symptomatic support is needed, supporting patients in situations with recurrent or episodic manifestations. Anastrozole is often applied in clinical settings that involve acute or unstable symptom patterns related to systemic imbalance. Its use in this context provides supportive relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Hormone-Driven Symptoms

Quick Fact: Anastrozole helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability during symptomatic periods. It is commonly used to help with conditions characterized by periods of heightened symptoms related to estrogen-sensitive disease.

Regulatory References

  1. FDA DailyMed: Anastrozole Indications
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Анастрозол?

Eligibility for Anastrozole is strictly defined by regulatory bodies (such as the FDA and EMA) and is primarily based on a patient's endocrine status and pre-existing medical conditions. The medicine is classified as prescription-only and is subject to mandatory restrictions.

Official Eligibility Constraints

Classification Population/Condition Regulatory Status
Eligible Population Postmenopausal women Approved Use
Contraindicated Premenopausal women Must Not Use
Contraindicated Pregnant or breastfeeding women Must Not Use
Contraindicated Hypersensitivity to Anastrozole or excipients Must Not Use
Conditional Use Moderate to severe hepatic impairment Use with Caution
Conditional Use Severe renal impairment ( GFR < 30 mL/ min) Use with Caution
Age Restriction Children and adolescents Not Recommended

Anastrozole is strictly contraindicated for women of premenopausal endocrine status because its mechanism is not suitable and its safety has not been established in this group. Furthermore, use is not recommended for children and adolescents due to insufficient data on efficacy and safety. Patients with severe liver or kidney impairment are advised to use the medication with caution.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Anastrozole interactions is defined by constraints with other hormonal therapies and a low potential for metabolic conflicts.

Interaction-Related Restrictions

Classification Interacting Product Official Restriction Basis
Contraindicated Estrogen-containing products (e.g., Estradiol) Pharmacodynamic Antagonism; may diminish Anastrozole's action.
Avoid/Not Recommended Tamoxifen (SERM) Co-administration reduces Anastrozole plasma concentration by approximately 27% and provides no additional benefit.

Metabolic and Pharmacokinetic Interactions

The regulatory data indicates that Anastrozole is unlikely to cause clinically significant inhibition of CYP P450-mediated metabolism of other drugs. Studies with test substrates like Antipyrine and Warfarin demonstrated no alteration in their clearance or activity, supporting a low metabolic interaction risk.

Food: The drug's extent of absorption is not affected by food, meaning there are no mandatory timing restrictions regarding meals.

Population-Specific Notes: Official pharmacokinetic studies note that Anastrozole clearance is approximately 30% lower in subjects with stable hepatic cirrhosis and renal clearance is 50% lower in severe renal impairment. These observations reflect alterations in drug exposure based on patient condition, as documented in regulatory information.

Advertisements

Mechanism of Action

Highly Selective Inhibition of the Aromatase Enzyme

Anastrozole exerts its effect by functioning as a competitive, reversible inhibitor of the Aromatase enzyme (CYP19A1). This specialized enzyme is responsible for the crucial, rate-limiting step of converting androgen precursors (like testosterone) into circulating estrogens (mathbf17beta-Estradiol and Estrone). By specifically binding to the enzyme's active site, the drug functionally blocks this conversion process.

Systemic Suppression of Peripheral Estrogen Biosynthesis

The molecular blockade of Aromatase, which is primarily active in peripheral tissues (e.g., adipose tissue, muscle), leads to a rapid and sustained interruption of the estrogen biosynthesis pathway. This cascade results in a profound systemic reduction in circulating estrogen levels, creating an endocrine state characterized by suppressed estrogen levels and a functional withdrawal of estrogenic stimulation. This targeted suppression of the hormone is the resultant physiological consequence that shapes the drug's action. However, the mechanism is constrained by the subsequent biological override in pre-menopausal patients due to a compensatory increase in ovarian hormone production.

Advertisements

Dosage and Administration Information

How to Use Анастрозол — Official Administration Guidelines

Anastrozole administration is defined by a highly standardized, fixed-dose daily regimen, as outlined in official guidelines. This usage protocol is centered on the oral route of administration using the 1 mg film-coated tablet.


Administration Scope

Feature Official Rule
Route of administration Oral administration only.
Dosing schedule 1 mg taken as a single dose.
Timing in relation to meals (if applicable) May be taken with or without food.
Preparation requirements (if applicable) The tablet is to be swallowed whole; no preparation is required.
Age-group administration rules Elderly patients (≥65 years): No dosage adjustment is necessary.
Missed-dose rules If a dose is missed, skip the forgotten dose and take the next scheduled dose at the usual time. Do not double doses.
Special procedural conditions No dose adjustment needed for mild to moderate renal or hepatic impairment.

Instruction Classifications (High-Level)

Classification Official Pattern
Administration method type Oral
Frequency pattern Once daily (qDay)
Regulatory basis Standardized across major international guidelines
Use-context constraints Continuous daily dosing; Long-term use pattern; Food-independent timing.

Resulting Procedural Structure

Official step sequence:

  • Administer the prescribed 1 mg tablet by mouth.
  • Take the dose once every 24 hours.
  • Continue the administration for a period of up to five years (for adjuvant use) or until disease progression (for advanced conditions).

Connection to the overall use protocol (2–4 sentences):

This protocol establishes a straightforward, long-term, fixed-dose usage pattern. The official instructions define a continuous 1 mg oral dose taken once daily that is standardized across adult populations and is not contingent on food intake or minor organ function variations. This structure emphasizes consistency in daily administration over an extended duration.

Advertisements

Recent Clinical Evidence

Anastrozole: Recent Clinical Evidence

Clinical research has focused on the use of anastrozole in managing hormone-receptor-positive breast cancer. Anastrozole, an aromatase inhibitor, is studied for its ability to reduce circulating estrogen levels in postmenopausal women.

Adjuvant and Extended Adjuvant Settings

Studies in the adjuvant setting (following initial treatment) have examined the use of anastrozole compared to tamoxifen or placebo. Findings from large, long-term randomized controlled trials (RCTs) indicate that treatment with anastrozole for five years is associated with similar or favorable outcomes regarding disease-free survival compared to tamoxifen, specifically in estrogen-receptor-positive early breast cancer. Research continues to investigate the optimal duration of therapy.

In the extended adjuvant setting (treatment after five years of initial therapy), studies have explored whether continuing anastrozole for an additional five years is associated with a further reduction in recurrence risk in certain patient groups. Evidence suggests a potential benefit in disease-free survival, though this observation must be balanced against potential long-term side effects and individual risk profiles.

Combination Therapies

Contemporary research investigates anastrozole in combination with targeted therapies. Studies have explored whether adding targeted agents, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, to anastrozole is associated with improved progression-free survival in patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. Clinical trial data support the use of these combinations as a standard initial treatment for this advanced disease stage.

Researchers continue to monitor long-term safety profiles, particularly concerning bone mineral density and cardiovascular events, which are commonly assessed in trials comparing anastrozole to other endocrine agents.

Key Studies & References

  1. Early and locally advanced breast cancer: diagnosis and management (NICE Guideline NG101)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Анастрозол (FAQ)


Q: What are the differences between bone pain and joint pain linked to Anastrozole use?

A: Regulatory documents list arthralgia (joint pain and stiffness) and bone pain or osteoporosis (decreased bone mineral density) as separate adverse reactions occurring at different frequencies.

This distinction indicates that they are recognized as distinct events: joint pain relates to aches in the joints, while the long-term risk of bone pain is associated with the potential for increased skeletal bone loss.


Q: Are mood changes, anxiety, or low energy known side effects of Anastrozole?

A: Official labeling classifies asthenia (low energy, weakness, or fatigue) as a very common side effect.

In official labeling, adverse reactions reported include depression and mood disturbances.


Q: What pre-existing heart conditions require caution when taking Anastrozole?

A: The official safety information warns of an increased risk of ischemic cardiovascular events in patients with pre-existing heart disease or cardiovascular disorders.

Therefore, the official prescribing information states that the medicine should be used with caution in patients who have a history of heart conditions.


Q: Does Anastrozole affect liver function or require regular liver monitoring?

A: Official documents list uncommon events like Hepatitis (liver inflammation) as potential adverse reactions. Furthermore, caution is advised for patients with moderate to severe liver impairment.

Regulatory information indicates that monitoring of liver function tests may be recommended at baseline and as clinically indicated.


Q: Does Anastrozole interact with common non-prescription pain relievers?

A: Official sources generally state that there are very few medicines that affect how Anastrozole works in the body.

It is important for a patient to consult a healthcare professional regarding the suitability of any new medication or supplement, including common non-prescription pain relievers.


Q: How does Anastrozole differ from Tamoxifen in terms of its mechanism of action?

A: Anastrozole is classified as a non-steroidal Aromatase Inhibitor (AI); it works by blocking the enzyme that produces estrogen in the body.

In contrast, Tamoxifen is a Selective Estrogen Receptor Modulator (SERM), which works by blocking estrogen receptors on cells rather than blocking estrogen production itself.


Q: Can a patient with a history of osteoporosis use Anastrozole?

A: Official prescribing information states that caution is required for the use of Anastrozole in patients with known osteoporosis or risk factors for bone loss.

This is due to the drug’s intended effect of lowering estrogen, which is associated with a risk of decreased bone mineral density.


Q: What is the role of Anastrozole in patients who have already had surgery or chemotherapy?

A: Anastrozole is commonly indicated for use in the adjuvant setting, which means it is given to patients following initial treatments like surgery or chemotherapy.

It is used for an extended duration to help reduce the risk of recurrence of the condition.


Q: What are the signs of a serious allergic reaction to Anastrozole?

A: Official safety information lists severe, although very rare, reactions such as Angioedema (swelling of the face, tongue, or throat) and Stevens-Johnson Syndrome (blistering skin rash).

These events are considered medical emergencies.


Q: How quickly does Anastrozole begin to lower the body's estrogen production?

A: Anastrozole begins to work very quickly after a dose is taken.

Studies show that circulating estrogen (serum estradiol) levels are reported to be suppressed by approximately 70% within 24 hours of starting the 1 mg daily dose.


Q: Are there specific types of hormone-sensitive conditions that Anastrozole is used for?

A: According to official documentation, Anastrozole is indicated for the treatment of hormone receptor-positive early or advanced breast cancer in women who are postmenopausal.

It is also approved in some regions for use in risk reduction for women considered to be at high risk.


Q: What is the definition of 'postmenopausal' as it relates to starting Anastrozole treatment?

A: Regulatory labeling requires the patient to be officially postmenopausal to begin treatment with Anastrozole.

In medical terms, this typically means a patient is no longer having menstrual periods due to natural menopause or surgical intervention, as defined by medical criteria.


Q: Are there any known circumstances where men might be prescribed Anastrozole?

A: While the primary indication is for postmenopausal women, the medicine might sometimes be used to treat breast cancer in men.

Official data on side effects in this population are limited, but the effects are generally considered to be similar.


Q: Is there an officially recommended time of day for taking Anastrozole?

A: Regulatory guidance specifies taking the medicine once a day but does not designate a specific time (e.g., morning or evening).

Consistency is important, and taking the dose at approximately the same time each day is typically recommended to maintain steady levels in the body.


Q: Is joint discomfort from Anastrozole permanent, or can it improve over time?

A: Studies and evidence indicate that aromatase inhibitors, including Anastrozole, do not cause permanent joint or muscle damage.

In many cases, side effects such as joint discomfort, low mood, and tiredness often tend to improve as the body adjusts to the medicine during the first few months of treatment.


Q: How long after starting treatment do side effects like hot flashes typically begin?

A: Due to the medicine's rapid and profound action in lowering estrogen levels, side effects similar to menopausal symptoms, such as hot flashes, may begin very quickly.

Reports indicate these side effects may appear within a day of starting the medication.


Q: Can Anastrozole cause sleep disturbances like insomnia or changes in sleep patterns?

A: Yes, official safety information lists difficulty sleeping (insomnia) as a common side effect of the medicine.

Somnolence (drowsiness or sleepiness) is also listed as a common adverse reaction that can affect sleep patterns.


Q: Is 'brain fog' or difficulty concentrating recognized as a potential side effect?

A: While not always listed as a primary side effect, reports of difficulty concentrating are noted by authoritative patient information groups.

This symptom is often linked to the common side effects of fatigue and disturbed sleep (due to insomnia or hot flashes) caused by the medicine.


Q: What side effects related to vaginal or sexual health are linked to Anastrozole use?

A: The medicine's action of significantly suppressing estrogen can lead to effects similar to natural menopause.

Common side effects listed include vaginal dryness or irritation and a reduction in sex drive (libido).


Q: Can Analgesics be used to manage the common aches and pains associated with Anastrozole?

A: If managing mild aches and pains, guidance from a healthcare professional or pharmacist is important to determine the suitability of a painkiller.

This ensures that the selected analgesic is appropriate for the individual's overall health and treatment plan.


Q: Can Anastrozole cause an increase in blood cholesterol levels?

A: Yes, regulatory documents list Hypercholesterolaemia (an increase in blood cholesterol levels) as a Common side effect.

Monitoring of cholesterol levels is often part of the routine medical management during treatment.


Q: Are there specific tests used to monitor bone health while a patient is taking Anastrozole?

A: Due to the associated risk of decreased bone mineral density and fractures, monitoring of bone mineral density is recommended.

This monitoring is typically performed at baseline (before starting treatment) and as clinically indicated during the course of therapy.


Q: Does taking Anastrozole increase the risk of developing Carpal Tunnel Syndrome?

A: Official safety information lists Carpal Tunnel Syndrome (a condition causing pain, numbness, and tingling in the hand and arm) as a Common adverse reaction.


Q: Are there any known interactions between Anastrozole and dietary or herbal supplements?

A: Official guidance states that herbal remedies or supplements intended for menopause symptoms should not be taken.

This caution is given because these products may contain ingredients that could interfere with the medicine's estrogen-suppressing action.


Q: What is the safety information regarding consuming soy or phytoestrogen products while taking Anastrozole?

A: Authoritative patient information indicates that concentrated phytoestrogen products, particularly those intended to relieve menopausal symptoms, are typically advised against.

These products may contain compounds that could counteract the drug's intended anti-estrogen effects.


Q: Does consuming alcohol affect the safety or effectiveness of Anastrozole?

A: Available patient information indicates that the consumption of alcohol does not appear to affect the safety or usefulness of the medicine.

However, it is important to discuss alcohol consumption with the treating healthcare team.


Q: How does Anastrozole differ from Letrozole or Exemestane?

A: Anastrozole, along with Letrozole, is classified as a non-steroidal Aromatase Inhibitor (AI), meaning they work similarly by blocking the aromatase enzyme.

It differs from Exemestane, which belongs to a different structural category known as a steroidal AI.


Q: Is it expected that the effects and side effects of Anastrozole will be the same for all patients?

A: No. As with all medicines, the effects and side effects of Anastrozole are subject to individual biological variation.

Therefore, the occurrence and severity of side effects can and often do vary from person to person.


Q: What is the risk of weight gain specifically linked to taking Anastrozole?

A: Clinical trial data indicate no statistically significant difference in the amount of weight gained when comparing patients taking Anastrozole to those taking Tamoxifen or a placebo (inactive pill).

Weight changes are generally not considered a primary, direct side effect of the medicine itself.


Q: Does the body develop tolerance to the side effects of Anastrozole over time?

A: Official patient information indicates that side effects such as difficulty sleeping, tiredness, and low mood are often reported to improve as the body adjusts to the medicine.

This improvement is typically noted during the first few months of treatment.

Advertisements

How should Анастрозол be stored and disposed of?

The storage and disposal of Anastrozole tablets must comply strictly with conditions set by regulatory labeling.

Storage Conditions

Requirement Official Condition (Regulatory Range)
Temperature Controlled room temperature: 20 C to 25 C (68 F to 77 F) [1, 2]
Protection Keep in a dry place; protect from moisture and light [2, 3]
Prohibited Must be kept from freezing [2]
Container Must be kept in the original container, tightly closed [1, 3]

Child Safety and Disposal

The medication must be stored securely and kept out of the sight and reach of children [1, 4].

For disposal, unused or expired Anastrozole tablets must not be discarded in household trash or poured into wastewater [4, 5]. The official regulatory instruction is to return the product to a local pharmacy or an approved drug take-back program for proper disposal according to environmental regulations [5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Анастрозол found in:

A-Z Index: